Review
Promising new agents for treatment of patients with colorectal cancer
Affiliations
- PMID: 9786316
Item in Clipboard
Review
Promising new agents for treatment of patients with colorectal cancer
Semin Oncol.
1998 Oct.
Abstract
Colorectal cancer continues to be a major problem. There are a number of new agents with promising clinical activity, including the multitargeted antifolate LY 231514 and the thymidylate synthesis inhibitor capecitabine. In addition, other agents have shown promising preclinical activity against the disease: 6-hydroxymethylacylfulvene (HMAF; MGI 114), LY 295501, bizelesin (U-7779; NSC615291), and ONYX-015. Finally, several agents may prevent colorectal cancer through prevention of the formation of colorectal polyps (eg, cyclooxygenase inhibitors).
Similar articles
-
The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.Oncologist. 1999;4(6):478-87. Oncologist. 1999. PMID: 10631692 Review.
-
Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer.Oncologist. 2006 Oct;11(9):1018-24. doi: 10.1634/theoncologist.11-9-1018. Oncologist. 2006. PMID: 17030644 Review.
-
Thymidylate synthase inhibitors in colorectal cancer.Semin Oncol. 2000 Oct;27(5 Suppl 10):83-7. Semin Oncol. 2000. PMID: 11049037 Review. No abstract available.
-
The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.Stem Cells. 2000;18(3):166-75. doi: 10.1634/stemcells.18-3-166. Stem Cells. 2000. PMID: 10840069 Review.
-
Thymidylate synthase inhibitors as anticancer agents: from bench to bedside.Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S80-9. doi: 10.1007/s00280-003-0625-9. Epub 2003 Jun 18. Cancer Chemother Pharmacol. 2003. PMID: 12819937 Review.
Cited by
-
Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience.Invest New Drugs. 2006 Mar;24(2):99-110. doi: 10.1007/s10637-006-5932-7. Invest New Drugs. 2006. PMID: 16502353 Review.
-
Role of caspases in 5-FU and selenium-induced growth inhibition of colorectal cancer cells.Anticancer Res. 2008 Nov-Dec;28(6A):3579-92. Anticancer Res. 2008. PMID: 19189638 Free PMC article.
-
A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.Br J Cancer. 2004 May 4;90(9):1710-4. doi: 10.1038/sj.bjc.6601783. Br J Cancer. 2004. PMID: 15150625 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical